- Home
- ASMB vs SQNS Comparison
ASMB vs SQNS Comparison
Compare ASMB & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- SQNS
- Stock Information
- Founded
- ASMB 2005
- SQNS 2003
- Country
- ASMB United States
- SQNS France
- Employees
- ASMB N/A
- SQNS N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- SQNS Semiconductors
- Sector
- ASMB Health Care
- SQNS Technology
- Exchange
- ASMB Nasdaq
- SQNS Nasdaq
- Market Cap
- ASMB 130.2M
- SQNS 46.5M
- IPO Year
- ASMB 2010
- SQNS 2011
- Fundamental
- Price
- ASMB $18.14
- SQNS $1.45
- Analyst Decision
- ASMB Strong Buy
- SQNS Strong Buy
- Analyst Count
- ASMB 3
- SQNS 1
- Target Price
- ASMB $33.00
- SQNS $7.50
- AVG Volume (30 Days)
- ASMB 41.3K
- SQNS 1.0M
- Earning Date
- ASMB 08-07-2025
- SQNS 08-22-2025
- Dividend Yield
- ASMB N/A
- SQNS N/A
- EPS Growth
- ASMB N/A
- SQNS N/A
- EPS
- ASMB N/A
- SQNS 2.16
- Revenue
- ASMB $32,154,000.00
- SQNS $38,858,000.00
- Revenue This Year
- ASMB $0.04
- SQNS N/A
- Revenue Next Year
- ASMB N/A
- SQNS $93.87
- P/E Ratio
- ASMB N/A
- SQNS $0.67
- Revenue Growth
- ASMB 148.33
- SQNS 40.06
- 52 Week Low
- ASMB $7.75
- SQNS $0.95
- 52 Week High
- ASMB $19.93
- SQNS $4.28
- Technical
- Relative Strength Index (RSI)
- ASMB 68.18
- SQNS 36.51
- Support Level
- ASMB $17.45
- SQNS $1.40
- Resistance Level
- ASMB $18.92
- SQNS $1.51
- Average True Range (ATR)
- ASMB 0.87
- SQNS 0.20
- MACD
- ASMB -0.05
- SQNS -0.04
- Stochastic Oscillator
- ASMB 74.68
- SQNS 15.80
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.